PARP抑制剂在小细胞肺癌靶向治疗中的进展  

Progress of PARP inhibitors in targeted therapy of small cell lung cancer

作　　者：刘利 朱思齐 孙梦颖 何敬东[1] Liu Li;Zhu Siqi;Sun Mengying;He Jingdong(Department of Oncology,Affiliated Huai'an No.1 People's Hospital of Nanjing Medical University,Huai'an 223300,China)

机构地区：[1]南京医科大学附属淮安第一医院肿瘤内科,淮安223300

出　　处：《国际肿瘤学杂志》2023年第6期368-372,共5页Journal of International Oncology

摘　　要：小细胞肺癌(SCLC)是一种发展迅速的恶性肿瘤,具有高度异质性并易产生耐药,预后通常不佳。多聚ADP核糖聚合酶(PARP)抑制剂可靶向作用于DNA损伤反应通路,阻止DNA修复,从而发挥抗肿瘤作用。目前在SCLC治疗方案中既有PARP抑制剂单药治疗,也有与DNA损伤剂或免疫检查点抑制剂联合治疗。尽管目前研究结果有限,但可以看到PARP抑制剂可能是SCLC靶向治疗的突破口。Small cell lung cancer(SCLC)is a rapidly developing malignant tumor,which is highly heterogeneous and prone to drug resistance,and the prognosis is usually poor.Poly ADP-ribose polymerase(PARP)inhibitors target the DNA damage response pathway,preventing DNA repair,thereby exerting anti-tumor effects.Currently,PARP inhibitors are used as monotherapy or in combination with DNA-damaging agents or immune checkpoint inhibitors in the treatment of SCLC.Although the current research results are limited,it can be seen that PARP inhibitors may be a breakthrough in the targeted therapy of SCLC.

关 键 词：小细胞肺癌 多(ADP核糖)聚合酶抑制剂 DNA修复 分子靶向治疗 靶向制剂 

分 类 号：R734.2[医药卫生—肿瘤]